Pulmonary Kaposi's Sarcoma in a Patient Infected with Human Immunodeficiency Virus 1: Successful Treatment with Paclitaxel

肺部卡波西氏肉瘤發生在人類免疫缺乏病毒感染者身上－成功以紫杉醇治療

陳宗家(Tsung-Chia Chen) ； 林俊良(Chun-Liang Lin) ； 李鼎專(Ting-Chuan Li) ； 賴銘淙(Ming-Tsung Lai) ； 曾婷玉(Ting-Yu Tseng)

《內科學誌》 29卷3期 (2018/06) Pp. 175-179

https://doi.org/10.6314/JIMT.201806_29(3).08

摘要

The incidence of Kaposi's sarcoma on HIV-1-infected patients declined in the post-antiretroviral therapy (ART) era. Furthermore, pulmonary Kaposi's sarcoma constituted a smaller proportion of all Kaposi's sarcoma patients. The treatment of Kaposi's sarcoma depends on the disease severity. Chemotherapy with ART is crucial in the treatment of pulmonary Kaposi's sarcoma. Moreover, paclitaxel and pegylated liposomal doxorubicin are used for the treatment of this disease, and their effects are comparable. Various doses and schedules were adopted by different clinicians. In this study, we present a patient diagnosed with pulmonary Kaposi's sarcoma, treated with high dose of paclitaxel (200 mg/m^2, every 2 weeks) for this disease entity and achieved an excellent outcome.

關鍵字

Pulmonary Kaposi's sarcoma ； HIV ； Paclitaxel

並列摘要

我們在此報告一位罹患肺部卡波西氏肉瘤的愛滋病患者，經診斷後以較高劑量(200 mg/ m^2)的紫杉醇治療，兩周一次共治療三次後痊癒，經追蹤沒有復發的個案報告。